Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00638937 | AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2018 | clinicaltrials |
| NCT01871805 | A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 134 | Hoffmann-La RocheINDUSTRY | 2 | Aug 21, 2018 | clinicaltrials |
| NCT01207063 | Adaptive Radiotherapy in Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 40 | Maastricht Radiation OncologyOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT00654420 | A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007) | completed | Phase 2 | 95 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT00527735 | Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 334 | Bristol-Myers SquibbINDUSTRY | 8 | Jul 18, 2018 | clinicaltrials |
| NCT01922583 | AUY922 in Patient With Stage IV NSCLC(NSCLC) | completed | Phase 2 | 31 | National Taiwan University HospitalOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT02005458 | Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy | completed | Phase 2 | 80 | Xiamen Amoytop Biotech Co., Ltd.INDUSTRY | 1 | Jul 17, 2018 | clinicaltrials |
| NCT02025114 | Selumetinib in Combination With Gefitinib in NSCLC Patients | completed | Phase 1 / Phase 2 | 34 | National Taiwan University HospitalOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT01557959 | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT01234038 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel(NSCLC) | completed | Phase 1 / Phase 2 | 116 | Ionis Pharmaceuticals, Inc.INDUSTRY | 4 | Jun 27, 2018 | clinicaltrials |
| NCT00890825 | AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients | completed | Phase 2 | 88 | AstraZenecaINDUSTRY | 12 | Jun 20, 2018 | clinicaltrials |
| NCT01864681 | Combination of Metformin With Gefitinib to Treat NSCLC(CGMT) | completed | Phase 2 | 224 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jun 20, 2018 | clinicaltrials |
| NCT01829113 | Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer(Spruce) | completed | Phase 2 | 155 | SCRI Development Innovations, LLCOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT00870870 | A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before | completed | Phase 2 | 64 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 1, 2018 | clinicaltrials |
| NCT00687297 | Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 162 | PrECOG, LLC.OTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT02979821 | Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) | completed | Phase 2 | 6 | Korean Association for the Study of Targeted TherapyOTHER | 1 | May 24, 2018 | clinicaltrials |
| NCT01139775 | A Study in Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 76 | Eli Lilly and CompanyINDUSTRY | 2 | May 18, 2018 | clinicaltrials |
| NCT01204099 | Study of PX-866 and Docetaxel in Solid Tumors | completed | Phase 1 / Phase 2 | 223 | Cascadian Therapeutics Inc.INDUSTRY | 2 | May 16, 2018 | clinicaltrials |
| NCT01029678 | Concomitant Radio-chemotherapy in the Elderly(RACCOSA) | completed | Phase 2 | 48 | University Hospital, LimogesOTHER | 1 | May 3, 2018 | clinicaltrials |
| NCT00078390 | Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 9 | ShionogiINDUSTRY | 1 | May 2, 2018 | clinicaltrials |
| NCT01588145 | Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients | completed | Phase 1 / Phase 2 | 273 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Apr 24, 2018 | clinicaltrials |
| NCT02444819 | Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy | completed | Phase 2 | 33 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Apr 24, 2018 | clinicaltrials |
| NCT02284139 | Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects | completed | Phase 2 / Phase 3 | 90 | Dong-A University HospitalOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT00266877 | Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 172 | Puma Biotechnology, Inc.INDUSTRY | 5 | Apr 13, 2018 | clinicaltrials |
| NCT00410904 | AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2018 | clinicaltrials |
| NCT01854034 | Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR | completed | Phase 2 | 29 | Massachusetts General HospitalOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT00654030 | Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer | completed | Phase 2 | 12 | Edward HirschowitzOTHER | 1 | Apr 9, 2018 | clinicaltrials |
| NCT00111839 | Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer | completed | Phase 2 | 150 | EMD SeronoINDUSTRY | 3 | Apr 6, 2018 | clinicaltrials |
| NCT01395758 | Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 96 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Apr 3, 2018 | clinicaltrials |
| NCT01752400 | AUY922 for Advanced ALK-positive NSCLC | completed | Phase 2 | 6 | Massachusetts General HospitalOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT00923312 | Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 46 | CureVacINDUSTRY | 2 | Mar 20, 2018 | clinicaltrials |
| NCT00462995 | Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)(SELECT) | completed | Phase 2 | 25 | University Health Network, TorontoOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT00997334 | Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC | completed | Phase 2 | 60 | David M. Jackman, MDOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT00399789 | A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 121 | AEterna ZentarisINDUSTRY | 1 | Feb 22, 2018 | clinicaltrials |
| NCT00072631 | Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 43 | OSI PharmaceuticalsINDUSTRY | 1 | Feb 8, 2018 | clinicaltrials |
| NCT00138203 | Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jan 30, 2018 | clinicaltrials |
| NCT01378962 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER) | completed | Phase 2 | 50 | Hoffmann-La RocheINDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00577707 | Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON) | completed | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01676714 | Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer | completed | Phase 2 | 10 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00400803 | Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer | completed | Phase 2 | 38 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT02182050 | Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer | completed | Phase 2 | 73 | Boehringer IngelheimINDUSTRY | 0 | Dec 28, 2017 | clinicaltrials |
| NCT00230126 | OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer | completed | Phase 2 | 57 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 26, 2017 | clinicaltrials |
| NCT03371550 | A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy(TAXCIS) | completed | Phase 2 | 44 | Centre Antoine LacassagneOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT00093756 | Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2017 | clinicaltrials |
| NCT00362882 | Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00783705 | Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia | completed | Phase 2 | 85 | National Cancer Institute (NCI)NIH | 2 | Dec 5, 2017 | clinicaltrials |
| NCT01648517 | Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy | completed | Phase 2 | 60 | Yonsei UniversityOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT02388919 | Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）(ALTER0303) | completed | Phase 2 / Phase 3 | 439 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 18, 2017 | clinicaltrials |
| NCT00985855 | Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer | completed | Phase 2 | 91 | Institut de Cancérologie de la LoireOTHER | 1 | Sep 14, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Aug 29, 2018source: clinicaltrials